A5048070921- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Radiopharmaceutical Chemistry and Applications
- Bladder and Urothelial Cancer Treatments
- Bone health and treatments
- Cancer Treatment and Pharmacology
- Boron Compounds in Chemistry
- Medical Imaging Techniques and Applications
- Advanced X-ray and CT Imaging
- Urinary Bladder and Prostate Research
- Urologic and reproductive health conditions
- Hepatocellular Carcinoma Treatment and Prognosis
- Orthopaedic implants and arthroplasty
- Restless Legs Syndrome Research
- Chemical Reactions and Isotopes
- Radiation Dose and Imaging
- Cancer, Lipids, and Metabolism
- Childhood Cancer Survivors' Quality of Life
- Multiple and Secondary Primary Cancers
- Statistical Methods in Clinical Trials
- Nuclear Materials and Properties
- Anesthesia and Sedative Agents
- Lung Cancer Diagnosis and Treatment
- Pain Management and Treatment
St James's University Hospital
2013-2024
Leeds Teaching Hospitals NHS Trust
2009-2020
Oslo University Hospital
2017
Mount Vernon Hospital
2012
The Christie NHS Foundation Trust
2012
Beatson West of Scotland Cancer Centre
2012
Royal Preston Hospital
2012
Nottingham University Hospitals NHS Trust
2012
Velindre Cancer Centre
2012
Regional Cancer Center
2006
Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with particles. We assessed the efficacy and safety of radium-223 as compared placebo, in addition to best standard care, men castration-resistant prostate cancer metastases.
The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose in patients localised prostate cancer. Preliminary findings reported after 5 years follow-up showed that escalated-dose improved biochemical progression-free survival. Based on the sample size calculation, we planned analyse overall survival when 190 deaths occurred; target has now been reached, a median 10 follow-up.RT01 phase 3, open-label, international, randomised controlled enrolling men...
Focal therapy as a treatment option for localized prostate cancer (PCa) is an increasingly popular and rapidly evolving field.
Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT postoperative after radical prostatectomy is unclear.
The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety adjuvant RT versus an observation policy with salvage prostate-specific antigen (PSA) failure.
In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety castration-resistant prostate cancer patients symptomatic bone metastases. Long-term monitoring underlies a comprehensive and risk/benefit assessment.To report updated ALSYMPCA safety, including long-term up to 3 yr after the first injection.Safety analyses from phase randomized trial included receiving ≥1 study-drug injection (600 301 placebo). Patients...
LBA4512 The full, final text of this abstract will be available at abstract.asco.org 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Monday edition ASCO Daily News.
The phase 3 ALSYMPCA trial enrolled metastatic castration-resistant prostate cancer patients with or without baseline opioid use. To assess the efficacy and safety of radium-223 dichloride (radium-223) versus placebo in by Nine hundred twenty one at 136 centers globally. Radium-223 (50 kBq/kg, intravenous injection) every 4 wk for six cycles matching placebo, each plus best standard care. Primary endpoint (overall survival [OS]), main secondary endpoints, were evaluated Additional analyses...
PurposeEarly and accurate localization of lesions in patients with biochemical recurrence (BCR) prostate cancer may guide salvage therapy decisions. The present study, 18F-Fluciclovine PET/CT biochemicAL reCurrence Of Prostate caNcer (FALCON; NCT02578940), aimed to evaluate the effect 18F-fluciclovine on management men BCR cancer.Methods MaterialsMen a first episode after curative-intent primary were enrolled at 6 UK sites. Patients underwent positron emission tomography/computed tomography...
To compile the safety profile and quality of life (QoL) data for patients with metastatic castration-resistant prostate cancer (mCRPC) treated cabazitaxel in UK Early Access Programme (UK EAP).A total 112 participated at 12 centres. All had mCRPC disease progression during or after docetaxel. Patients received 25 mg/m(2) every 3 weeks prednisolone 10 mg daily up to cycles. Safety assessments were performed before each cycle QoL was recorded alternate cycles using EQ-5D-3L questionnaire...
Abstract Objective The use of prostate brachytherapy (BT) in the management cancer is increasing. BT often chosen because its perceived lower toxicity when compared with other radical therapy options. Rarely however serious complications can occur. One such complication recto‐urethral fistula (RUF). We report incidence RUF following at our centre and review potential factors development. Method A prospectively collected database was used to identify cases among 1455 patients treated a single...